AMACR expression in colorectal cancer is associated with left-sided tumor localization.
Standard
AMACR expression in colorectal cancer is associated with left-sided tumor localization. / Marx, Andreas; Simon, Philipp; Simon, Ronald; Mirlacher, Martina; Izbicki, Jakob R.; Yekebas, Emre F.; Kaifi, Jussuf; Terracciano, Luigi; Sauter, Guido.
in: VIRCHOWS ARCH, Jahrgang 453, Nr. 3, 3, 2008, S. 243-248.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - AMACR expression in colorectal cancer is associated with left-sided tumor localization.
AU - Marx, Andreas
AU - Simon, Philipp
AU - Simon, Ronald
AU - Mirlacher, Martina
AU - Izbicki, Jakob R.
AU - Yekebas, Emre F.
AU - Kaifi, Jussuf
AU - Terracciano, Luigi
AU - Sauter, Guido
PY - 2008
Y1 - 2008
N2 - Alpha-methylacyl-CoA racemase (AMACR) is an enzyme playing an important role in the beta-oxidation of branched-chain fatty acids and fatty acid derivatives. Altered expression levels of AMACR have been described in various cancers including colorectal cancer (CRC). To determine the potential prognostic impact of AMACR expression, we analyzed 1,315 CRC on a tissue microarray (TMA) by immunohistochemistry (IHC). Clinical follow-up data were available from all cancer patients. Positive AMACR staining was observed in 1,074 (81.7%) of the 1,315 cases including 276 cancers with weak (21.0%) and 798 cancers with strong staining (60.7%). AMACR IHC was significantly associated with tumor grade, stage, non-mucinous phenotype, and left-sided tumor localization (p <0.0001 each). AMACR positivity was observed in 65.8% of cancers from the right-sided colon, in 73.2% of cancers from the colon transversum, in 81.1% of cancers from the colon descendens, and in 88.9% of the distal left-sided cancers (sigma and rectum; p <0.0001). However, AMACR staining results were unrelated to clinical outcome. It is concluded that AMACR cannot serve as a prognostic marker in CRC. We hypothesize that the association of AMACR expression with tumor localization may be related to differences in the metabolism/exposure to fatty acids occurring along the colon.
AB - Alpha-methylacyl-CoA racemase (AMACR) is an enzyme playing an important role in the beta-oxidation of branched-chain fatty acids and fatty acid derivatives. Altered expression levels of AMACR have been described in various cancers including colorectal cancer (CRC). To determine the potential prognostic impact of AMACR expression, we analyzed 1,315 CRC on a tissue microarray (TMA) by immunohistochemistry (IHC). Clinical follow-up data were available from all cancer patients. Positive AMACR staining was observed in 1,074 (81.7%) of the 1,315 cases including 276 cancers with weak (21.0%) and 798 cancers with strong staining (60.7%). AMACR IHC was significantly associated with tumor grade, stage, non-mucinous phenotype, and left-sided tumor localization (p <0.0001 each). AMACR positivity was observed in 65.8% of cancers from the right-sided colon, in 73.2% of cancers from the colon transversum, in 81.1% of cancers from the colon descendens, and in 88.9% of the distal left-sided cancers (sigma and rectum; p <0.0001). However, AMACR staining results were unrelated to clinical outcome. It is concluded that AMACR cannot serve as a prognostic marker in CRC. We hypothesize that the association of AMACR expression with tumor localization may be related to differences in the metabolism/exposure to fatty acids occurring along the colon.
M3 - SCORING: Zeitschriftenaufsatz
VL - 453
SP - 243
EP - 248
JO - VIRCHOWS ARCH
JF - VIRCHOWS ARCH
SN - 0945-6317
IS - 3
M1 - 3
ER -
